'Moffitt Cancer Center Announces Strategic Collaboration With AstraZeneca To Accelerate Oncology Cell Therapies'
'Moffitt Cancer Center Announces Strategic Collaboration With AstraZeneca To Accelerate Oncology Cell Therapies'
The collaboration aims to address cell therapy development challenges and expand cell therapies' reach to more patients in the United States and beyond. A key focus will be on advancing clinical studies to investigate cell therapies in solid tumors and further optimizing clinical operations to streamline and expedite the delivery of autologous cell therapies to patients.Moffitt Cancer Center announces today a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR T) therapies.
莫菲特癌症中心今天宣佈與阿斯利康展開戰略合作，旨在加速細胞療法，尤其是嵌合抗原受體T細胞（CAR T細胞）和T細胞受體（TCR T細胞）療法的發展。
Under this collaboration, AstraZeneca will have priority access to Moffitt's leading clinical environment and forge strong connections between physician-scientists to accelerate the investigation of novel cell therapies.
在這次合作中，阿斯利康將優先獲得莫菲特領先的臨床環境，並在醫學科學家之間建立緊密聯繫，加快對新型細胞療法的研究。
Advances in cell therapy, including CAR Ts and TCR Ts, are reshaping cancer care by offering potential new treatments for cancers with limited treatment options. The field has grown exponentially since the first CAR T therapies were approved in 2017. Moffitt was pivotal in the clinical trials that led to several FDA approvals for cell therapies and continues to grow its capabilities in this field, with an extensive network of cancer centers across the United States.
細胞療法，包括CAR T和TCR T，正在重新定義癌症護理，爲治療選擇有限的癌症患者提供潛在的新治療方法。這個領域自2017年首個CAR T療法獲得批准以來，發展迅猛。莫菲特在導致多種FDA批准細胞療法的臨床試驗中扮演了關鍵角色，並且在這個領域不斷擴大其能力，擁有遍佈全美的癌症中心網絡。
The collaboration aims to address cell therapy development challenges and expand cell therapies' reach to more patients in the United States and beyond. A key focus will be on advancing clinical studies to investigate cell therapies in solid tumors and further optimizing clinical operations to streamline and expedite the delivery of autologous cell therapies to patients.
合作旨在應對細胞療法研發的挑戰，將細胞療法的覆蓋面擴大到更多美國及其他地區的患者。其中一個關鍵焦點是推動臨床研究，以探索在實體腫瘤中應用細胞療法，並進一步優化臨床運作，以便更高效地將自體細胞療法交付給患者。
"We are excited to collaborate with AstraZeneca to push the boundaries of what's possible in cancer treatment. By combining our clinical expertise with AstraZeneca's innovative pipeline of investigational cell therapies, global footprint and leadership in oncology, we aim to bring potential new cell therapies to patients faster and more efficiently," said Patrick Hwu, M.D., president and CEO of Moffitt.
莫菲特的總裁兼首席執行官Patrick Hwu 萬.D表示：「我們很高興與阿斯利康合作，推動癌症治療的可能性。通過將我們的臨床專業知識與阿斯利康創新的細胞療法管線、全球影響力和腫瘤學領域領導地位相結合，我們旨在更快、更高效地爲患者帶來潛在的新型細胞療法。」
"This collaboration will strengthen our connections with the Moffitt Cancer Center to accelerate the development of our autologous cell therapy pipeline as we strive to redefine cancer treatment for more people living with hematological and solid cancers," said Carsten Linnemann, Head of Oncology Cell Therapy Clinical Development, AstraZeneca.
阿斯利康腫瘤學細胞療法臨床開發負責人Carsten Linnemann表示：「這次合作將加強我們與莫菲特癌症中心的聯繫，加速我們自體細胞療法管線的發展，爲更多患有血液和實體腫瘤的人重新定義癌症治療。」
